Uncoupling protein 2 is upregulated in melanoma cells and contributes to the activation of Akt/mTOR and ERK signaling

Li,Jinran; Jia,Yuxi; An,Lin; Niu,Chunbo; Cong,Xianling; Zhao,Yunfeng

doi:10.3892/ijo.2020.5010

Uncoupling protein 2 is upregulated in melanoma cells and contributes to the activation of Akt/mTOR and ERK signaling

Authors:
- Jinran Li
- Yuxi Jia
- Lin An
- Chunbo Niu
- Xianling Cong
- Yunfeng Zhao
View Affiliations

Affiliations: Department of Dermatology, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Pathology, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Pharmacology, Toxicology and Neurosciences, LSU Health Sciences Center, Shreveport, LA 71130, USA
Published online on: March 12, 2020 https://doi.org/10.3892/ijo.2020.5010
Pages: 1252-1261

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to characterize the expression of uncoupling protein 2 (UCP2) in melanoma and to study the potential mechanisms underlying the involvement of UCP2 in melanomagenesis using human melanoma cell lines. The expression of UCP2 was evaluated in specimens from normal control subjects, patients with compound nevus, and patients with cutaneous and mucosal melanoma. Stable knockdown of UCP2 was achieved in human melanoma cell lines, which were used to examine whether UCP2 knockdown affects the mitochondrial membrane potential and intracellular levels of ATP, reactive oxygen species and lactate. Cell proliferation, invasion, spheroid formation and cisplatin sensitivity were also evaluated in the UCP2 knockdown cells. Finally, the effects of UCP2 knockdown on the Akt/mammalian target of rapamycin (mTOR) and extracellular signal‑regulated kinase (ERK) pathways, which are important oncogenic pathways during melanomagenesis, were evaluated. Relatively high expression of UCP2 was detected in human melanoma specimens, which was correlated with Clark level and Breslow thickness. Knockdown of UCP2 suppressed cell proliferation, invasion and spheroid formation, and increased the sensitivity of melanoma cells to cisplatin. Furthermore, the UCP2 knockdown cells exhibited inhibition of Akt/mTOR signaling and ERK activation. Therefore, human melanoma tissues exhibit relatively high UCP2 expression, which may be implicated in the mechanisms underlying tumor progression. The potential role of UCP2 in melanomagenesis may involve enhancing the Akt/mTOR and mitogen‑activated protein kinase/ERK pathways.

View Figures

View References

1	Linares MA, Zakaria A and Nizran P: Skin cancer. Prim Care. 42:645–659. 2015. View Article : Google Scholar : PubMed/NCBI
2	Haenssle HA, Mograby N, Ngassa A, Buhl T, Emmert S, Schön MP, Rosenberger A and Bertsch HP: Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol. 152:291–298. 2016. View Article : Google Scholar
3	Tsao H, Chin L, Garraway LA and Fisher DE: Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155. 2012. View Article : Google Scholar : PubMed/NCBI
4	Moon H, Donahue LR, Choi E, Scumpia PO, Lowry WE, Grenier JK, Zhu J and White AC: Melanocyte stem cell activation and translocation initiate cutaneous melanoma in response to UV exposure. Cell Stem Cell. 21:665–678. 2017. View Article : Google Scholar : PubMed/NCBI
5	Ježek P, Holendová B, Garlid KD and Jabůrek M: Mitochondrial uncoupling Proteins: Subtle regulators of cellular redox signaling. Antioxid Redox Signal. 29:667–714. 2018. View Article : Google Scholar
6	Rial E, González‑Barroso MM, Fleury C and Bouillaud F: The structure and function of the brown fat uncoupling protein UCP1: Current status. Biofactors. 8:209–219. 1998. View Article : Google Scholar
7	Toda C and Diano S: Mitochondrial UCP2 in the central regulation of metabolism. Best Pract Res Clin Endocrinol Metab. 28:757–764. 2014. View Article : Google Scholar : PubMed/NCBI
8	Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A, Seydoux J, Muzzin P and Giacobino JP: Uncoupling protein-3: A new member of the mitochondrial carrier family with tissue‑specific expression. FEBS Lett. 408:39421997. View Article : Google Scholar : PubMed/NCBI
9	Mao W, Yu XX, Zhong A, Li W, Brush J, Sherwood SW, Adams SH and Pan G: UCP4, a novel brain‑specific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett. 443:326–330. 1999. View Article : Google Scholar : PubMed/NCBI
10	Yu XX, Mao W, Zhong A, Schow P, Brush J, Sherwood SW, Adams SH and Pan G: Characterization of novel UCP5/BMCP1 isoforms and differential regulation of UCP4 and UCP5 expression through dietary or temperature manipulation. FASEB J. 14:1611–1618. 2000. View Article : Google Scholar : PubMed/NCBI
11	Brandi J, Cecconi D, Cordani M, Torrens-Mas M, Pacchiana R, Dalla Pozza E, Butera G, Manfredi M, Marengo E, Oliver J, et al: The antioxidant uncoupling protein 2 stimulates hnRNPA2/B1, GLUT1 and PKM2 expression and sensitizes pancreas cancer cells to glycolysis inhibition. Free Radic Biol Med. 101:305–316. 2016. View Article : Google Scholar : PubMed/NCBI
12	Elorza A, Hyde B, Mikkola HK, Collins S and Shirihai OS: UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis. J Biol Chem. 283:30461–30470. 2008. View Article : Google Scholar : PubMed/NCBI
13	Dando I, Pacchiana R, Pozza ED, Cataldo I, Bruno S, Conti P, Cordani M, Grimaldi A, Butera G, Caraglia M, et al: UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism. Free Radic Biol Med. 113:176–189. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li W, Zhang C, Jackson K, Shen X, Jin R, Li G, Kevil CG, Gu X, Shi R and Zhao Y: UCP2 knockout suppresses mouse skin carcinogenesis. Cancer Prev Res (Phila). 8:487–491. 2015. View Article : Google Scholar
15	Sreedhar A, Petruska P, Miriyala S, Panchatcharam M and Zhao Y: UCP2 overexpression enhanced glycolysis via activation of PFKFB2 during skin cell transformation. Oncotarget. 8:95504– 95515. 2017. View Article : Google Scholar : PubMed/NCBI
16	Sreedhar A, Lefort J, Petruska P, Gu X, Shi R, Miriyala S, Panchatcharam M and Zhao Y: UCP2 upregulation promotes Plcγ-1 signaling during skin cell transformation. Mol Carcinog. 56:2290–2300. 2017. View Article : Google Scholar : PubMed/NCBI
17	Rossi S, Cordella M, Tabolacci C, Nassa G, D'Arcangelo D, Senatore C, Pagnotto P, Magliozzi R, Salvati A, Weisz A, et al: TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness. J Exp Clin Cancer Res. 37:3262018. View Article : Google Scholar : PubMed/NCBI
18	Bhatia S, Tykodi SS and Thompson JA: Treatment of metastatic melanoma: An overview. Oncology (Williston Park). 23:488–496. 2009.
19	Rofstad EK, Wahl A, Davies Cde L and Brustad T: Growth characteristics of human melanoma multicellular spheroids in liquid-overlay culture: Comparisons with the parent tumour xenografts. Cell Tissue Kinet. 19:205–216. 1986.PubMed/NCBI
20	Bosman FT, de Goeij AF and Rousch M: Quality control in immunocytochemistry: Experiences with the oestrogen receptor assay. J Clin Pathol. 45:120–124. 1992. View Article : Google Scholar : PubMed/NCBI
21	Baffy G, Derdak Z and Robson SC: Mitochondrial recoupling: A novel therapeutic strategy for cancer? Br J Cancer. 105:469–474. 2011. View Article : Google Scholar : PubMed/NCBI
22	Gill KS, Fernandes P, O'Donovan TR, McKenna SL, Doddakula KK, Power DG, Soden DM and Forde PF: Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response. Biochim Biophys Acta. 1866:87–105. 2016.PubMed/NCBI
23	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI
24	Calero R, Morchon E, Martinez-Argudo I and Serrano R: Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 406:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
25	Babchia N, Calipel A, Mouriaux F, Faussat AM and Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: Interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci. 51:421–429. 2010. View Article : Google Scholar
26	Mao XH, Chen M, Wang Y, Cui PG, Liu SB and Xu ZY: MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN. Mol Carcinog. 56:886–894. 2017. View Article : Google Scholar
27	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
28	Eggermont AM, Spatz A and Robert C: Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar
29	Rigel DS: Epidemiology of melanoma. Semin Cutan Med Surg. 29:204–209. 2010. View Article : Google Scholar
30	Li W, Nichols K, Nathan CA and Zhao Y: Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors. Cancer Biomark. 13:377–383. 2013. View Article : Google Scholar
31	Estrada Y, Dong J and Ossowski L: Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 22:66–76. 2009. View Article : Google Scholar
32	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
33	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
34	Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, et al: Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest. 117:719–729. 2007. View Article : Google Scholar : PubMed/NCBI
35	Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, et al: Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2:76–85. 2013. View Article : Google Scholar : PubMed/NCBI
36	Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M and Holmen SL: AKT1 activation promotes development of melanoma metastases. Cell Rep. 13:898–905. 2015. View Article : Google Scholar : PubMed/NCBI
37	Dai DL, Martinka M and Li G: Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol. 23:1473–1482. 2005. View Article : Google Scholar : PubMed/NCBI
38	Polivka Jr J and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 142:164–175. 2014. View Article : Google Scholar
39	Yang Y, Luo Z, Hao Y, Ba W, Wang R, Wang W, Ding X and Li C: mTOR-mediated Na+/Ca2+ exchange affects cell proliferation and metastasis of melanoma cells. Biomed Pharmacother. 92:744–749. 2017. View Article : Google Scholar : PubMed/NCBI
40	Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C and Meier F: Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol. 129:1500–1515. 2009. View Article : Google Scholar
41	Yu X, Luo A, Liu Y, Wang S, Li Y, Shi W, Liu Z and Qu X: MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer. 14:2082015. View Article : Google Scholar : PubMed/NCBI
42	Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794–798. 1991.PubMed/NCBI
43	Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A and Sotgia F: Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: The seed and soil also needs 'fertilizer'. Cell Cycle. 10:2440–2449. 2011. View Article : Google Scholar : PubMed/NCBI
44	Cheng WC, Tsui YC, Ragusa S, Koelzer VH, Mina M, Franco F, Läubli H, Tschumi B, Speiser D, Romero P, et al: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nat Immunol. 20:206–217. 2019. View Article : Google Scholar : PubMed/NCBI